3月13日 - ** 药物开发商AltimmuneALT.O股价在延长交易中上涨近3%，随后跌幅收窄
** 公司表示正计划将其实验性减肥药培美度肽作为酒精使用障碍和酒精相关肝病的治疗药物进行试验
** 计划在第二季度开始培美度肽治疗酒精使用障碍的中期试验，并在第三季度开始另一项治疗酒精相关肝病的中期试验
** 公司的药物培美度肽在一项中期试验中显示可帮助患者平均减轻体重 15.6
** 截至上一交易日收盘，股价累计下跌 27.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.